drugset / Trial / NCT00269750
A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare the efficacy and safety of OROS® oxybutynin to that of Ditropan® (immediate-release oxybutynin) for the treatment of patients with urge or mixed urinary incontinence. Oxybutynin is an antispasmodic, anticholinergic medication for the treatment of the symptoms of overactive bladder.
Timeline
- Start
- 1996-07
- Primary completion
- —
- Completion
- 1997-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxybutynin | Small molecule | 5 mg | Oral |
| Subject | Oxybutynin | Small molecule | 10 mg | Oral |
| Subject | Oxybutynin | Small molecule | 15 mg | Oral |
| Subject | Oxybutynin | Small molecule | 20 mg | Oral |
| Subject | Oxybutynin | Small molecule | 25 mg | Oral |
| Subject | Oxybutynin | Small molecule | 30 mg | Oral |